Vaxart, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Nov 12, 2019 and accepted by EDGAR at Nov 12, 2019, 17:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $454.0k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $5.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $3.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $11.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$4.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$10.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-07-01 to 2019-09-30 | $84.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2019-01-01 to 2019-09-30 | $288.0k | us-gaap:InterestExpense |
| Income tax | 3 months2019-07-01 to 2019-09-30 | $31.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-01-01 to 2019-09-30 | $294.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$5.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$12.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | −$0.96 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$9.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-01-01 to 2019-09-30 | $838.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $19.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $21.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $42.7m | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $9.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $23.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | $18.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-19-022502. Last ingested by Listed: Nov 5, 2026, 18:48 ET. Listed shows no prices and gives no investment advice.